• Ginekol Pol · Jul 2010

    [Recombinant factor VIIa for treatment of postpartum hemorrhage due to uterine atony].

    • Grazyna Michalska-Krzanowska.
    • Oddział Intensywnej Terapii SPSK Nr1 PAM, Szczecin-Police. grazyna195@op.pl
    • Ginekol Pol. 2010 Jul 1;81(7):544-8.

    BackgroundObstetric hemorrhage is a life-threatening situation for every mother and child. NovoSeven is a recombinant, activated factor VII which may be useful in the treatment of uncontrollable hemorrhage. It accelerates hemostasis by direct activation of the factor X.Material And MethodsThe author presents her own experience with administration of NovoSeven at the Intensive Care Unit, Medical University Szczecin in the treatment of bleedings after standard methods failure. NovoSeven was given to patients in postpartum hemorrhage due to uterine atony who did not present any signs of haemostatic disorders.ResultsIn all presented cases, bleeding symptoms abated and hemodynamic stabilization was obtained shortly after the drug administration.ConclusionNovoSeven is a very effective agent in the treatment of postpartum hemorrhage.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.